|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
VG Life Sciences, Inc. (VGLS) Expands Ovarian Cancer Trial; Approved to Study Treatment of Breast, Colon, Lung, Liver and Pancreas Cancer
1/15/2013 9:42:44 AM
SAN MARINO, Calif.--(BUSINESS WIRE)--VG Life Sciences (OTC Pink: VGLS), has received approval from the Institutional Review Board of the University of Texas Health Science Center San Antonio to expand the types of cancers being studied in the Company’s ongoing physician-initiated Phase 1 clinical trial. The IRB action allows the study to immediately broaden scope to the treatment of all solid tumors, which includes a wide and diverse range of cancer types including breast, colon, lung, liver and pancreas cancer. Effective immediately, principal investigator Dr. Tyler Curiel will begin screening patients with all solid tumors to study the safety of hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexevar™ by Bayer AG). VG Life Sciences holds the exclusive worldwide license to the body of patents underlying the use of MDT compounds in the treatment of cancers.
|
|
|
|
|
|
|
|
|
|
|